Adaptin Bio (APTN) EBIAT (2023 - 2026)
Adaptin Bio recorded quarterly EBIAT of -$1.1 million in Q1 2026, up 16.22% quarter-over-quarter from -$1.4 million in Q4 2025, and down 90.04% year-over-year from -$11.5 million in Q1 2025.
Adaptin Bio's EBIAT history runs 4 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, EBIAT fell 90.04% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$5.7 million (down 68.64% YoY), while the FY2025 annual figure was -$5.2 million, down 65.49% from the prior year.
- EBIAT came in at -$1.1 million for Q1 2026 at Adaptin Bio, up from -$1.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$4250.0 in Q1 2023 to a low of -$1.7 million in Q3 2025.
- A 4-year average of -$732447.3 and a median of -$818738.0 in 2024 frame the typical range for EBIAT.
- Across the five-year window, EBIAT sank 19164.42% in 2024 and slumped 51.29% in 2025, its largest moves.
- Adaptin Bio's EBIAT stood at -$34155.0 in 2023, then sank by 2408.67% to -$856836.0 in 2024, then tumbled by 59.66% to -$1.4 million in 2025, then climbed by 16.22% to -$1.1 million in 2026.
- According to Business Quant data, EBIAT over the past three periods registered -$1.1 million, -$1.4 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.15 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | -1.68 Mn |
| Jun 30, 2025 | -1.52 Mn |
| Mar 31, 2025 | -603,084.00 |
| Dec 31, 2024 | -856,836.00 |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -818,738.00 |
| Mar 31, 2024 | -339,432.00 |
| Dec 31, 2023 | -34,155.00 |
| Sep 30, 2023 | -42,938.00 |
| Jun 30, 2023 | -4,250.00 |
| Mar 31, 2023 | -4,250.00 |